Is ABTs mission focused upon diagnostics, therapy, or remediation?
ABT’s central mission is the commercialization of phage-based treatment of bacterial infection. Thus, ABT’s focus is upon therapy and environmental remediation rather than diagnostics. ABT is not involved in producing genetically-modified organisms. Q: What kind of therapies and environmental remediation drive ABT’s business model? In the republics of the former Soviet Union, ABT and its production affililiate, Biopharm-L, are engaged in the production and marketing of an extensive line of phage-based medical treatments. ABT’s global strategy is focused primarily upon the identification of agricultural, aquacultural, and environmental problems for which phage therapy can provide potential remediation. As phage therapy gains wider acceptance outside of the former “Eastern Bloc,” ABT hopes to lead the way in providing phage therapy as a legitimate treatment for the entire spectrum of bacterial diseases. Q: What about the competition posed by purportedly “new and better” antibiotics? A: “
